Skip to content
10-Q

Quarterly Report

PATHFINDER CELL THERAPY, INC.

0001213900-14-008191

← back to feed
Filed
Nov 14, 2014 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2014 · Sep 30, 2014 667.16M sh
Stockholders Equity Q3 2014 · Sep 30, 2014 −$5.65M
Stockholders Equity Q3 2014 · Dec 31, 2013 −$4.55M
Stockholders Equity Q3 2014 · Dec 31, 2012 −$2.85M
Current Liabilities Q3 2014 · Sep 30, 2014 $5.72M
Current Liabilities Q3 2014 · Dec 31, 2013 $4.71M
Current Assets Q3 2014 · Sep 30, 2014 $37K
Current Assets Q3 2014 · Dec 31, 2013 $119K
Total Assets Q3 2014 · Sep 30, 2014 $70K
Total Assets Q3 2014 · Dec 31, 2013 $155K
Gross Profit Q3 2014 · Sep 30, 2014 $0
Gross Profit Q3 2014 · Sep 30, 2014 $0
Gross Profit Q3 2014 · Sep 30, 2013 $4K
Gross Profit Q3 2014 · Sep 30, 2013 $30K
Cost Of Revenue Q3 2014 · Sep 30, 2014 $0
Cost Of Revenue Q3 2014 · Sep 30, 2014 $0
Cost Of Revenue Q3 2014 · Sep 30, 2013 $4K
Cost Of Revenue Q3 2014 · Sep 30, 2013 $24K
Revenue Q3 2014 · Sep 30, 2014 $0
Revenue Q3 2014 · Sep 30, 2014 $0
Revenue Q3 2014 · Sep 30, 2013 $8K
Revenue Q3 2014 · Sep 30, 2013 $54K
Operating Cash Flow Q3 2014 · Sep 30, 2013 −$1.26M
Cash And Equivalents Q3 2014 · Sep 30, 2013 $51K
Cash And Equivalents Q3 2014 · Dec 31, 2012 $9K
Sga Expense restated Q3 2014 · Sep 30, 2013 $213K
Sga Expense restated Q3 2014 · Sep 30, 2013 $743K
Rd Expense restated Q3 2014 · Sep 30, 2013 $106K
Rd Expense restated Q3 2014 · Sep 30, 2013 $459K
Net Income Q3 2014 · Sep 30, 2013 −$372K
Net Income Q3 2014 · Sep 30, 2013 −$1.24M
Operating Income Q3 2014 · Sep 30, 2013 −$320K
Operating Income Q3 2014 · Sep 30, 2013 −$1.35M